Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
JAZZ
JAZZ
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
JAZZ News
Sellas Life Sciences Hits 52-Week High Amid Buyout Speculation
Jun 29 2026
Yahoo Finance
Jazz Pharmaceuticals' Zepzelca Phase 3 Trial Fails to Meet Primary Endpoint
Jun 23 2026
Fool
Biotech Sector Sees FDA Approvals and Layoffs
Jun 19 2026
NASDAQ.COM
Jazz Pharmaceuticals and AbCellera Collaborate on Antibody Development
Jun 17 2026
NASDAQ.COM
Jazz Pharmaceuticals and AbCellera Sign $848M Agreement for Antibody Development
Jun 17 2026
seekingalpha
Jazz Pharmaceuticals Partners with AbCellera for Antibody Development
Jun 17 2026
PRnewswire
Jazz Pharmaceuticals Partners with AbCellera for Antibody Development
Jun 17 2026
Newsfilter
Jazz Pharmaceuticals Unveils New Research Advances at SLEEP 2026
Jun 16 2026
PRnewswire
Jazz Pharmaceuticals Q1 Earnings Analysis and Investment Recommendations
Jun 15 2026
Yahoo Finance
Jazz Pharmaceuticals' LAGOON Trial Results Fail to Meet Expectations
Jun 12 2026
NASDAQ.COM
Jazz Pharmaceuticals' Zepzelca Fails Phase 3 Trial Endpoint
Jun 12 2026
NASDAQ.COM
Jazz Pharmaceuticals' Lung Cancer Therapy Trial Fails
Jun 12 2026
seekingalpha
Jazz Pharmaceuticals Announces LAGOON Trial Results for Zepzelca
Jun 12 2026
PRnewswire
Jazz Pharmaceuticals' LAGOON Trial Results Fail to Meet Primary Endpoint
Jun 12 2026
Newsfilter
Jazz Pharmaceuticals Presents 21 Abstracts at SLEEP 2026 Conference
Jun 04 2026
PRnewswire
Zanidatamab Shows Breakthrough Efficacy in HER2-Positive Cancer Treatments
May 27 2026
PRnewswire
Show More News
